547.74
price up icon2.40%   12.83
after-market Handel nachbörslich: 547.00 -0.74 -0.14%
loading
Schlusskurs vom Vortag:
$534.91
Offen:
$533.66
24-Stunden-Volumen:
817.89K
Relative Volume:
0.64
Marktkapitalisierung:
$56.52B
Einnahmen:
$14.09B
Nettoeinkommen (Verlust:
$4.50B
KGV:
13.94
EPS:
39.28
Netto-Cashflow:
$2.96B
1W Leistung:
+5.28%
1M Leistung:
+11.60%
6M Leistung:
-23.41%
1J Leistung:
-47.57%
1-Tages-Spanne:
Value
$529.69
$551.50
1-Wochen-Bereich:
Value
$514.79
$551.50
52-Wochen-Spanne:
Value
$476.49
$1,211.20

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Name
Firmenname
Regeneron Pharmaceuticals Inc
Name
Telefon
(914) 847-7000
Name
Adresse
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Name
Mitarbeiter
15,158
Name
Twitter
@regeneron
Name
Nächster Verdiensttermin
2025-02-04
Name
Neueste SEC-Einreichungen
Name
REGN's Discussions on Twitter

Vergleichen Sie REGN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-30 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2025-05-30 Herabstufung Wells Fargo Overweight → Equal Weight
2025-05-14 Hochstufung Citigroup Neutral → Buy
2025-04-22 Fortgesetzt Cantor Fitzgerald Overweight
2025-02-05 Hochstufung Leerink Partners Market Perform → Outperform
2025-01-16 Herabstufung UBS Buy → Neutral
2024-12-10 Fortgesetzt BofA Securities Underperform
2024-11-15 Eingeleitet Wolfe Research Outperform
2024-11-14 Eingeleitet Citigroup Neutral
2024-09-24 Herabstufung Leerink Partners Outperform → Market Perform
2024-03-12 Eingeleitet Bernstein Outperform
2024-01-12 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2023-11-09 Eingeleitet Deutsche Bank Hold
2023-11-03 Hochstufung Raymond James Mkt Perform → Outperform
2023-08-21 Hochstufung Canaccord Genuity Hold → Buy
2023-08-21 Bestätigt Oppenheimer Perform
2023-06-28 Herabstufung Canaccord Genuity Buy → Hold
2023-03-27 Hochstufung SVB Securities Market Perform → Outperform
2023-03-24 Hochstufung Jefferies Hold → Buy
2023-03-23 Hochstufung Raymond James Underperform → Mkt Perform
2023-01-30 Hochstufung Cowen Market Perform → Outperform
2023-01-20 Hochstufung JP Morgan Neutral → Overweight
2022-10-26 Herabstufung Raymond James Mkt Perform → Underperform
2022-10-17 Herabstufung Evercore ISI Outperform → In-line
2022-09-09 Hochstufung Jefferies Underperform → Hold
2022-09-09 Hochstufung Morgan Stanley Equal-Weight → Overweight
2022-07-25 Herabstufung SVB Leerink Outperform → Mkt Perform
2022-07-13 Eingeleitet Cantor Fitzgerald Neutral
2022-06-06 Eingeleitet Jefferies Underperform
2022-05-23 Eingeleitet SVB Leerink Outperform
2022-01-05 Herabstufung BofA Securities Neutral → Underperform
2022-01-03 Hochstufung Bernstein Mkt Perform → Outperform
2021-12-15 Herabstufung Bernstein Outperform → Mkt Perform
2021-12-09 Fortgesetzt Wells Fargo Overweight
2021-12-07 Fortgesetzt Cowen Market Perform
2021-12-06 Eingeleitet Goldman Buy
2021-11-19 Fortgesetzt BMO Capital Markets Outperform
2021-11-05 Herabstufung The Benchmark Company Buy → Hold
2021-06-29 Eingeleitet H.C. Wainwright Buy
2021-01-25 Hochstufung BMO Capital Markets Market Perform → Outperform
2021-01-13 Hochstufung The Benchmark Company Hold → Buy
2021-01-08 Hochstufung Citigroup Neutral → Buy
2020-10-05 Hochstufung Cantor Fitzgerald Neutral → Overweight
2020-08-20 Herabstufung The Benchmark Company Buy → Hold
2020-07-09 Hochstufung SunTrust Hold → Buy
2020-05-26 Hochstufung Wells Fargo Equal Weight → Overweight
2020-04-28 Herabstufung Citigroup Buy → Neutral
2020-04-17 Hochstufung The Benchmark Company Hold → Buy
2020-04-08 Eingeleitet The Benchmark Company Hold
2020-03-31 Eingeleitet Wolfe Research Peer Perform
2020-02-27 Eingeleitet Barclays Overweight
2020-02-26 Hochstufung Canaccord Genuity Hold → Buy
2020-02-26 Herabstufung Robert W. Baird Outperform → Neutral
2020-02-25 Hochstufung Jefferies Hold → Buy
2020-02-11 Hochstufung Argus Hold → Buy
2019-12-24 Eingeleitet Raymond James Mkt Perform
2019-12-16 Herabstufung Evercore ISI Outperform → In-line
2019-12-13 Hochstufung Credit Suisse Neutral → Outperform
2019-11-12 Eingeleitet SunTrust Hold
2019-11-07 Hochstufung Citigroup Neutral → Buy
2019-10-17 Fortgesetzt BofA/Merrill Neutral
2019-09-23 Hochstufung Guggenheim Neutral → Buy
Alle ansehen

Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten

pulisher
Jun 18, 2025

Regeneron Pharmaceuticals (REGN) Announces Key Decisions from 20 - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Regeneron Shareholders Approve Key Proposals at 2025 Meeting - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Grove Bank & Trust Has $514,000 Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Exchange Traded Concepts LLC Trims Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Factory Mutual Insurance Co. Buys 8,200 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 18, 2025
pulisher
Jun 17, 2025

Regeneron Steps Back, TTAM Aims To Reclaim 23andMe - Finimize

Jun 17, 2025
pulisher
Jun 17, 2025

FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction - BioPharma Dive

Jun 17, 2025
pulisher
Jun 17, 2025

Regeneron (REGN) Exits 23andMe Bidding War - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Regeneron is said to have declined a higher bid for 23andMe after Wojcicki's offer - Seeking Alpha

Jun 17, 2025
pulisher
Jun 17, 2025

PKO Investment Management Joint Stock Co Increases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 17, 2025
pulisher
Jun 17, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Schaper Benz & Wise Investment Counsel Inc. WI - MarketBeat

Jun 17, 2025
pulisher
Jun 17, 2025

Regeneron Pharmaceuticals Opts Out From Raising Offer for 23andMe - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Breakthroughs in Uveitis Treatment Market Drive Global Demand - openPR.com

Jun 17, 2025
pulisher
Jun 17, 2025

Harbor Capital Advisors Inc. Purchases New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 17, 2025
pulisher
Jun 16, 2025

23andme founder-led group outbids Regeneron for company - BioWorld MedTech

Jun 16, 2025
pulisher
Jun 16, 2025

Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer - Reuters

Jun 16, 2025
pulisher
Jun 16, 2025

Regeneron Pharmaceuticals says declined to submit new bid on 23andMe exceeding original $256 mln - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Fifth Third Bancorp Sells 952 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

JPMorgan Calls the Selloff Excessive, Trims Regeneron Pharmaceuticals, Inc. (REGN) Price Target - MSN

Jun 16, 2025
pulisher
Jun 16, 2025

Anne Wojcicki overcomes Regeneron in 23andMe assets battle - The Pharma Letter

Jun 16, 2025
pulisher
Jun 16, 2025

Anne Wojcicki’s Nonprofit Tops Bid for 23andMe Assets - Contract Pharma

Jun 16, 2025
pulisher
Jun 16, 2025

Patient Data Revolution: New Blockchain Platform Challenges Regeneron's $600M 23andMe Data Grab - Stock Titan

Jun 16, 2025
pulisher
Jun 16, 2025

BDF Gestion Has $2.82 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Dupixent demonstrated superiority over Xolair in chronic rhinosinusitis - The Pharma Letter

Jun 16, 2025
pulisher
Jun 16, 2025

Regeneron Pharmaceuticals Loses Bid as 23andMe to Sell Core Assets to TTAM for $305 Million - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Warther Private Wealth LLC - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Mn Services Vermogensbeheer B.V. Trims Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Silver Scott Health, Inc. Unveils Health Trust NFT to Empower Patient Data Control in Response to Regeneron's $600 Million 23andMe Bid - The Globe and Mail

Jun 16, 2025
pulisher
Jun 16, 2025

Sanofi, Regeneron Say Dupixent Outperforms Xolair in Phase 4 Respiratory Trial - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

RMR Wealth Builders Acquires Shares of 2,141 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Osprey Private Wealth LLC Makes New $2.24 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Pallas Capital Advisors LLC Invests $426,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Sanofi: positive data in chronic rhinosinusitis - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

Smithbridge Asset Management Inc. DE Invests $3.41 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Leerink Partnrs Issues Negative Forecast for REGN Earnings - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by NorthCrest Asset Manangement LLC - MarketBeat

Jun 16, 2025
pulisher
Jun 15, 2025

Sanofi, Regeneron Report Encouraging Results from Head-to-head Respiratory Study - MarketScreener

Jun 15, 2025
pulisher
Jun 15, 2025

Regeneron (REGN) and Sanofi's Dupixent Shows Superior Results in Key Phase 4 Trial | REGN Stock News - GuruFocus

Jun 15, 2025
pulisher
Jun 15, 2025

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study - GlobeNewswire

Jun 15, 2025
pulisher
Jun 15, 2025

Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute 1ere étude respiratoire de ph4 en comparaison directe … - GlobeNewswire Inc.

Jun 15, 2025
pulisher
Jun 15, 2025

Dupixent Outperforms Xolair in First-Ever Head-to-Head Trial for Nasal Polyps | REGN Stock News - Stock Titan

Jun 15, 2025
pulisher
Jun 15, 2025

Asio Capital LLC Has $2.53 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 15, 2025
pulisher
Jun 15, 2025

Greenwood Capital Associates LLC Invests $5.35 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 15, 2025
pulisher
Jun 15, 2025

Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis - Insider Monkey

Jun 15, 2025
pulisher
Jun 15, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Jun 15, 2025
pulisher
Jun 15, 2025

Wedmont Private Capital Lowers Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 15, 2025
pulisher
Jun 15, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Handelsbanken Fonder AB - MarketBeat

Jun 15, 2025
pulisher
Jun 15, 2025

Assenagon Asset Management S.A. Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 15, 2025
pulisher
Jun 14, 2025

New England Research & Management Inc. Invests $384,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Regeneron (REGN) Chosen as Backup Bidder in 23andMe Asset Sale | - GuruFocus

Jun 14, 2025
pulisher
Jun 14, 2025

Regeneron’s SWOT analysis: stock faces eylea challenges, pipeline potential - Investing.com

Jun 14, 2025

Finanzdaten der Regeneron Pharmaceuticals Inc-Aktie (REGN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Regeneron Pharmaceuticals Inc-Aktie (REGN) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
McCourt Marion
EVP Commercial
Nov 01 '24
Option Exercise
381.40
1,000
381,400
13,931
McCourt Marion
EVP Commercial
Nov 01 '24
Sale
844.61
1,000
844,610
12,931
$329.77
price up icon 2.39%
$545.11
price up icon 0.49%
biotechnology ONC
$244.32
price down icon 0.34%
$108.26
price up icon 0.70%
$98.24
price up icon 0.64%
Kapitalisierung:     |  Volumen (24h):